Navigation Links
Dulbecco's Phosphate Buffered Saline (DPBS) from Sigma-Aldrich

ProductsDulbecco's Phosphate Buffered Saline (DPBS) from Sigma-Aldrich
Company Sigma-Aldrich
Item Dulbecco's Phosphate Buffered Saline (DPBS)
Price 
Description With 36 mg/L sodium pyruvate, 50 mg/L streptomycin sulfate, 100 mg/L kanamycin monosulfate, 1000 mg/L glucose, calcium chloride, and magnesium chloride.

The use of a balanced salt solution (BSS) in tissue culture is generally attributed to early workers in the field. In 1885, Sydney Ringer developed a solution of inorganic salts designed to maintain contractility of mammalian heart tissue. A less specific salt solution was designed by Tyrode for use in work with mammalian cells in general. Tyrodes salt solution became the accepted fluid for diluting protein components of media of natural origin. Since that time, many other balanced salt solutions have been developed for use in tissue culture. The current role of a balanced salt solution in cell culture is multifaceted and can be divided into four principal functions:

  • serves as an irrigating, transporting and diluting fluid while maintaining intra- and extracellular osmotic balance;
  • provides cells with water and certain bulk inorganic ions essential for normal cell metabolism;
  • combined with a carbohydrate, such as glucose, provides the principal energy source for cell metabolism;
  • provides a buffering system to maintain the medium within the physiological pH range (7.2-7.6).

Sterile, Cell culture tested

Info Sigma-AldrichSigma-Aldrich
Sigma-Aldrich Corp.
St. Louis, MO, USA
Customer Service: 800-325-3010
Tech Support: 800-325-5832
Fax Number: 314-771-5757
Web Site: http://www.sigmaaldrich.com/
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Dulbeccos Modified Eagles Medium - high glucose (DME) from Sigma-Aldrich
2. Iscoves Modified Dulbeccos Medium (IMDM) from Sigma-Aldrich
3. Dulbeccos Phosphate Buffered Saline (DPBS) from Sigma-Aldrich
4. GIBCO Iscoves Modified Dulbeccos Medium (IMDM) (1X) liquid from Invitrogen
5. GIBCO Advanced D-MEM (Dulbeccos Modified Eagle Medium) (1X) liquid from Invitrogen
6. Dulbeccos Phosphate-Buffered Saline (D-PBS) powder from Invitrogen
7. GIBCO Dulbeccos Phosphate-Buffered Saline (D-PBS) (1X) liquid from Invitrogen
8. GIBCO Dulbeccos Phosphate-Buffered Saline (D-PBS) (1X) liquid from Invitrogen
9. Phosphate Colorimetric Assay Kit, EnzoLyte from AnaSpec
10. Phosphate Sensor from Invitrogen
11. Hexokinase/ Glucose-6-Phosphate Dehydrogenase from Roche Applied Science
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
Src cDNA Expression Kit (wild type)...
Biology Products:
(Date:3/23/2015)... , March 23, 2015 SoundView Technology Group ... NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was one ... feedback on their experience with the Wocket in multiple scenarios ... CVS, Whole Foods and other retailers, making both debit and ... Tuttle also says, "If the company meets their plans ...
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
(Date:3/20/2015)... Mar. 20, 2015 Research and Markets ... of the "India Sensors Market Forecast and ... The sensor market is projected to grow ... Consumer electronics, automotive, industrial and healthcare sectors ... the country. In addition, adoption of MEMS technology ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... honors four leaders in biomedical and health informatics ... Annual Symposium, Oct. 22-26, an event expected to ... over the coming week. The Signature Awards highlight ... sector have had significant, positive impact. , ...
... 20 OCTOBER 2011 EMBO today acknowledges the outstanding ... by awarding them life-long EMBO membership. Election to ... excellence and the exceptional achievements made by a life ... 1,500 of the best researchers in Europe and around ...
... COLUMBIA, Mo. The face and brain develop ... the embryo and continuing through adolescence. Now, University of ... characteristics of children with autism compared to those of ... the origins of autism. "There is ...
Cached Biology News:AMIA honors informatics professionals who are improving health, changing the world 2AMIA honors informatics professionals who are improving health, changing the world 346 outstanding life scientists elected to EMBO membership 2Autistic facial characteristics identified 2
(Date:4/27/2015)... CAMBRIDGE, Massachusetts y HEIDELBERG ... - Molecular Health obtiene la patente para un nuevo ... Aborda una necesidad no cubierta en el ...   Molecular Health ha anunciado hoy que ha ... Receptor". Esta última patente apoya el descubrimiento de Molecular ...
(Date:4/27/2015)... Jersey , 27 avril 2015 ... découverte médicamenteuse spécialisée dans le développement ... à soigner les infections bactériennes polypharmacorésistantes ... présentation de données prouvant les promesses ... TXA709, dans la lutte contre la ...
(Date:4/27/2015)... -- Haemonetics Corporation (NYSE: HAE ) today reported ... $226.5 million, down 6%.  Excluding currency impact, revenue ... reported a fourth quarter GAAP net loss of ... income, exclusive of transformation, restructuring and deal amortization ... and adjusted earnings per share were $0.47, up ...
(Date:4/27/2015)... MN (PRWEB) April 27, 2015 tru ... an agreement with Texas A&M University for the exclusive ... to as super-intensive raceway systems. The license agreement for ... Addison Lawrence, extends to countries such as China, Taiwan, ... Kingdom. , “We have had inquires from all ...
Breaking Biology Technology:Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 28Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 29